Cefdinir Dispersible Tablets

1. Antibacterial effect It has a wide range of antibacterial spectrum against Gram-positive and Gram-negative bacteria, especially against Staphylococcus and Streptococcus among Gram-positive bacteria. It has stronger antibacterial activity than previous oral cephalosporins, and its mode of action is bactericidal. It is stable to β-lactamase produced by various bacteria, and also has excellent antibacterial activity against β-lactamase producing bacteria. 2. Mechanism of action The mechanism of action is to prevent the synthesis of bacterial cell wall, and has strong affinity for penicillin binding protein (PBP) 1 (1a.lbs), 2, 3, but the active sites for different bacteria are different.

The following infections caused by strains of Staphylococcus, Streptococcus, Pneumococcus, Peptostreptococcus, Propionibacterium, Neisseria gonorrhoeae, Moraxella catarrhalis, Escherichia coli, Klebsiella, Proteus mirabilis, Providencia, Haemophilus influenzae, etc. that are sensitive to cefdinir: 1. Pharyngitis, tonsillitis, acute bronchitis, pneumonia; 2. Otitis media, sinusitis; 3. Pyelonephritis, cystitis, gonococcal urethritis; 4. Adnexitis, intrauterine infection, vestibular gland inflammation; 5. Mastitis, perianal abscess, secondary infection of trauma or surgical wound; 6. Folliculitis, furuncle, furuncle, carbuncle, infectious impetigo, erysipelas, cellulitis, lymphangitis, paronychia, subcutaneous abscess, atheroma infection, chronic pyoderma; 7. Blepharitis, sty

Disperse with water and take orally or swallow directly. The usual dose for adults is 0.1g (potency) once, 3 times a day. The usual dose for children is 9-18mg (potency)/kg per day, taken orally 3 times. The dose can be increased or decreased according to age and symptoms.

Among the 13,715 patients treated with this product, 354 cases (2.58%) reported adverse reactions (including abnormal laboratory data). The main adverse reactions were gastrointestinal symptoms (110 cases, 0.80%), such as diarrhea or abdominal pain; skin symptoms (31 cases, 0.23%), such as rash or itching. The main laboratory data abnormalities included elevated alanine aminotransferase (126 cases, 0.92%) and aspartate aminotransferase (89 cases, 0.65%); eosinophilia (41 cases, 0.30%). Other adverse reactions 1. Dermatology: Stevens-Johnson syndrome (<0.1%) or toxic epidermal necrolysis (<0.1%) may occur. Patients should be closely observed. If fever, headache, joint pain, erythema/blisters on the skin or mucous membranes, or tightness/burning/pain in the skin occur, the drug should be discontinued immediately and appropriate treatment should be given. 2. Allergic reactions: Allergic reactions such as dyspnea, erythema, angioedema, and urticaria may occur, with an incidence of <0.1%. The patient should be closely observed. If abnormal conditions occur, the drug should be discontinued immediately and appropriate treatment should be given. 3. Shock: Shock may occur, with an incidence of <0.1%. The patient should be closely observed. If symptoms such as discomfort, oral discomfort, wheezing, dizziness, urge to defecate, tinnitus, or sweating occur, the drug should be discontinued immediately and appropriate treatment should be given. 4. Hematology: Pancytopenia (<0.1%), agranulocytosis (<0.1%, initial symptoms are fever, sore throat, headache, discomfort), thrombocytopenia (<0.1%, initial symptoms are ecchymosis, purpura) or hemolytic anemia (<0.1%, initial symptoms are fever, hemoglobinuria, anemia symptoms) may occur. The patient should be closely observed. If abnormal conditions occur, the drug should be discontinued immediately and appropriate treatment should be given. 5. Colitis: Severe colitis (<0.1%), such as pseudomembranous colitis confirmed by bloody stools, may occur. Patients should be closely observed, and if symptoms such as abdominal pain or frequent diarrhea occur, the drug should be discontinued immediately and appropriate treatment should be given. 6. Interstitial pneumonia or PIE syndrome: Interstitial pneumonia or PIE syndrome (<0.1%), confirmed by fever, cough, dyspnea, abnormal chest X-ray examination, or eosinophilia, may occur. If such symptoms occur, the drug should be discontinued immediately and appropriate treatment should be given, such as the use of adrenal cortex hormones. 7. Kidney disease: Severe kidney disease (<0.1%), such as acute renal failure, may occur. Patients should be closely observed, and if abnormal conditions occur, the drug should be discontinued immediately and appropriate treatment should be given. 8. Fulminant hepatitis, abnormal liver function or jaundice: Severe hepatitis (<0.1%) may occur, such as fulminant hepatitis with significant elevation of alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase, abnormal liver function (<0.1%) or jaundice (<0.1%). Patients should be closely observed. If abnormal conditions occur, the drug should be discontinued immediately and appropriate treatment should be given.

Patients with a history of shock should not use this product. Patients with a history of allergy to penicillin or cephalosporin should use it with caution.

Keep in a dark place (avoid light and not exceed 20℃) and sealed.

50mg

24 months

Guangdong Bozhou Pharmaceutical Co., Ltd.

• Founded in:

  2000-12-07

• Address:

  Green Industrial Park, Jiedong Economic Development Zone, Jieyang City

• Tax NO.:

  9144520372599310X7

• Registered Funds:

  20 million yuan

• Email:

  Log in to view